Working Groups

Active?
Facet Toggle

A New Grand Bargain to Improve the Antimicrobial Market for Human Health
Amanda Glassman
et al.
June 27, 2022
While there have been high-level commitments from the World Health Assembly, the United Nations General Assembly (UNGA), the G20, and the G7 to tackle AMR, there has yet to be a fundamental change in how we purchase antimicrobials, or an international approach to improving access, fostering innovati...
Working Group on the Future of Global Health Procurement
Amanda Glassman
et al.
July 31, 2017
Many low-and lower-middle-income countries currently procure a large portion of their health commodities through centralized, donor-managed procurement mechanisms, and often at subsidized prices or as donations. Over the next several decades, however, the landscape of global health procurement will ...
The Unintended Consequences of Rich Countries’ Anti–Money Laundering Policies on Poor Countries
Alan Gelb
et al.
January 23, 2015
The Unintended Consequences of Rich Countries’ Anti-Money Laundering Policies on Poor Countries Working Group examined how rich countries might rebalance their policies to continue to protect against money laundering and terrorism financing without hindering the ability of people from poor countries...
The Future of IDA Working Group
Alan Gelb
et al.
September 15, 2014
Drug Resistance Working Group (November 2007 – June 2010)
Amanda Glassman
and
Prashant Yadav
September 10, 2014
Value for Money: An Agenda for Global Health Funding Agencies
Amanda Glassman
et al.
August 25, 2014
As international commitments become more ambitious and aid resources become increasingly constrained, global health funding agencies are seeking to improve the efficiency and impact of their investments. This growing “value for money” (VfM)  agenda aims to reduce costs, increase imp...
Beyond the Fence Study Group
Alan Gelb
et al.
July 10, 2014
The Beyond the Fence Study Group generates rigorous new research to explore how policy decisions on one side of the US-Mexico border ripple to the other side through illicit markets and to inform a policy debate on more bilateral approaches to innovative regulation.